Pharma & Biotech Industry Analysis, from Thought Leaders
Refine Search
Pharmaceutical
For the last five years or so, the narrative around the Swiss pharma giant Roche has been about a company that is likely to be hit harder than any other by the arrival of biosimilars, as they will ferociously erode sales from key products. 4 November 2019
Pharmaceutical
For more than a decade, the main area of interest and focus in oncology has been the astonishing progress of immuno-oncology therapies, led lately by the all-conquering Keytruda (pembrolizumab). 14 October 2019
Biotechnology
Analysts and crystal ball gazers in pharma love nothing more than a battle for dominance in a major market. 30 September 2019
Biotechnology
While there are several commonly-cited reasons for the present pre-eminence of the Cambridge-Boston biotech cluster, it's clear that the hub is greater than the sum of its parts. 16 September 2019
Biotechnology
The UK’s departure from the European Union looks likely to dent many sectors at least in the short to medium term, but the biopharmaceutical industry is one that might just continue to shine, however damaging the exit from the trade bloc proves to be. 23 August 2019
Pharmaceutical
The global pharmaceutical industry has spent well over a trillion dollars on research and development in the last ten years, and analysts expect annual investment levels to grow by around 3% annually, reaching up to $200 billion per year by 2022. 5 August 2019
Biotechnology
A look at the potential of microbiome-based therapies to transform medicine, and the progress of the closest such treatment to market. 30 July 2019
Pharmaceutical
IBM Watson Health has seen that being thought of as a pioneering company in applying artificial intelligence (AI) in healthcare can have its pros and cons, from a publicity point of view. 2 July 2019
Pharmaceutical
Gross domestic product (GDP) in Japan is about $5 trillion, and the country’s pharmaceutical market is one of the largest in the world, with figures from the Ministry of Health, Labour and Welfare (MHLW) indicating a market value of about $95 billion, including non-prescription medications. 28 June 2019
Pharmaceutical
Now that the warming Spanish sun has gone down on EULAR 2019, it’s worth considering what emerged of note from some of rheumatology’s leading players at the event in Madrid. 20 June 2019
Biotechnology
The flags have been furled, poster boards packed away, and ASCO planners are already getting ready for another year. Now, before attention turns to the next major event, we recap some of the key highlights and learnings from the industry’s preeminent cancer conference. 17 June 2019
Biotechnology
Despite a perceived lack of innovation that has moved the needle in the last five years, rheumatology remains a massively lucrative sector in which many of the world’s biggest pharma companies continue to earn the largest slice of their revenue. 7 June 2019
Pharmaceutical
“If Congress weakens patent laws, patients may never benefit from new treatments or cures." 30 May 2019
Biotechnology
It’s ASCO time again. The annual meeting of the American Society of Clinical Oncology (ASCO) is now almost upon us, with the event due to start in Chicago on Friday, May 31. 22 May 2019
Pharmaceutical
In a previous incarnation, Boehringer Ingelheim chief financial officer Michael Schmelmer spearheaded a bold approach to innovation which could bear digital fruit for the 130 year-old family-owned drugmaker. 10 May 2019
Biotechnology
Thankfully, the growing anti-microbial resistance (AMR) crisis is now getting some major headlines and airtime, so that even many lay people are getting a good grasp of the issues at the heart of this global priority. 2 May 2019
Pharmaceutical
The Pharmaceutical Price Regulation Scheme (PPRS) is dead; long live the Voluntary Scheme for Branded Medicines Pricing and Access (Voluntary Scheme)! 16 April 2019
Pharmaceutical
Representatives from pharmacy benefit managers (PBMs) were the latest to be grilled by lawmakers in Washington DC on Tuesday. 10 April 2019
Pharmaceutical
Judging which companies are topping the oncology research charts in any given quarter or year can be highly subjective, but sometimes drugmakers present a series of new findings at once that make their activities hard to ignore. 22 March 2019
Generics
Research shows some 79% of the American public view the cost of prescription drugs as unreasonable, and lawmakers and regulators are increasingly convinced the industry charges too much for its products. 8 March 2019
Biotechnology
A Feature analyzing M&A, licensing and partnerships in gene editing as CRISPR therapeutics enter the market and present new opportunities for pharma growth. 15 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. 22 September 2024
Pharmaceutical
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
Pharmaceutical
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Pharmaceutical
An Analysis of M&A activity in the CNS space. 26 July 2024
Pharmaceutical
The biopharmaceutical supply chain plays a pivotal role in ensuring the seamless delivery of therapeutics to patients. However, pharmaceutical supply chains face several challenges, including regulatory complexities, global competition, and the need for innovation. 26 July 2024
Pharmaceutical
Anticipation had been building for many weeks, but when the UK’s general election finally took place on 4 July, the outcome felt entirely inevitable. 9 July 2024
Biotechnology
The annual meeting of the American Society of Clinical Oncology (ASCO) is set to commence on 2 June in Chicago, with the highly anticipated plenary session taking place on the Sunday. 22 May 2024
Pharmaceutical
An analysis of the investment activity of Novartis in recent years. 5 April 2024
Pharmaceutical
An analysis of recent pharma activity in the metabolic diseases field and why obesity is a hot topic amongst investors. 8 March 2024
Pharmaceutical
When James Burt, the chief executive of lifecycle management healthcare company Pharmanovia, looks back at the mood in the pharma industry in 2023, he is happy to say that he is already experiencing a greater sense of optimism in 2024. 27 February 2024
Pharmaceutical
Danish drugmaker Lundbeck has its eye on steady growth over the medium term, a strategy which new chief executive Charl van Zyl believes could be key to the firm’s future success. 12 February 2024
Biotechnology
By Barbara Obstoj-Cardwell. Editor
In full year 2023, the total number of mergers and acquisitions (M&A) in the pharma and biotech sectors was 105, compared with 109 in 2022 and just 92 in 2021, according to tracking by The Pharma Letter (TPL). 4 January 2024
Biosimilars
In the two decades since biosimilars emerged on the world stage, their evolution has brought acceptance of the critical role they can play in making life-changing therapies more affordable. 22 December 2023
Pharmaceutical
A feature analyzing recent pharma activity in the hepatology field and why NASH remains unchartered territory. 20 December 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze